mitomycin has been researched along with Ovarian Neoplasms in 141 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Twenty-one patients with PC (12 gastric cancer, 5 colorectal cancer, 2 ovarian cancer, 1 pseudomyxoma peritonei, 1 malignant mesothelioma) were treated with CRS + HIPEC with hydroxycamptothecin 20 mg and mitomycin C 30 mg in 12,000 mL of normal saline at 43 +/- ." | 5.14 | Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases. ( al-shammaa Hassan, AH; Li, Y; Liu, SY; Lu, YL; Yang, GL; Yang, XJ; Yonemura, Y; Zhang, JW, 2009) |
| " More than 50% of centers administer oxaliplatin (74%), or mitomycin-C (65%) in colorectal cancer; cisplatin in gastric cancer (73%) and mesothelioma (74%)." | 3.88 | Current practice in cytoreductive surgery and HIPEC for metastatic peritoneal disease: Spanish multicentric survey. ( Barrios, P; Cascales-Campos, P; Esteve-Pérez, N; Morales-Soriano, R; Segura-Sampedro, JJ, 2018) |
| " In chromosomal breakage assays, all control cells were mitomycin C (MMC) resistant, but eight samples (five of the six high-risk and three of the eight ovarian cancer) were hypersensitive." | 3.73 | Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer. ( Akkari, Y; Ameziane, N; Bagby, GC; Bale, AE; Cain, JM; Cappuccini, F; Errami, A; Hays, LE; Keeble, W; Liu, HY; Olson, SB; Pejovic, T; Rathbun, RK; Rodgers, WH; Thuillier, P; Torimaru, Y; Yates, JE; Zwaan, CM, 2006) |
| "Twenty-nine women, ages 30-58 years, with advanced ovarian carcinoma were treated with a developmental combination chemotherapy regimen consisting of mitomycin C, etoposide, cisplatin, and carboplatin (MECCA)." | 3.69 | "MECCA": a developmental, dose-intensive, non-cross-resistant platinum-based chemotherapy for advanced ovarian cancer. ( Hoskins, PJ; Lee, N; McMurtrie, EM; Pike, JA; Swenerton, KD, 1996) |
| "The authors report the first results using intraperitoneal hyperthermic chemotherapy with mitomycin C or cisplatinum with protective hypothermia up to 32 degrees C in four cases of peritoneal carcinomatosis secondary to cancer of the ovary which was resistant to conventional treatment." | 3.68 | [Intraperitoneal chemo-hyperthermia in the treatment of peritoneal carcinomatosis of ovarian origin. Initial cases, physiopathologic data]. ( Brachet, A; Braillon, G; Carry, PY; Gilly, FN; Salle, B; Sayag, A, 1993) |
| "35 ovarian cancer patients with ascites have been treated intraperitoneally with mitomycin C or mitoxantrone or interferon beta or tumor necrosis factor (TNF)." | 3.68 | [Locoregional ascites therapy with cytostatic drugs and immune modulators in gynecologic neoplasms]. ( Chronides, A; Diedrich, K; Krebs, D; Mallmann, P; Wagner, U; Werner, A, 1991) |
| "Fourteen cases of adenocarcinoma with pleuritis carcinomatosa (lung cancer 10 cases, ovarian cancer 2 cases, colon cancer 2 cases) were treated with intra-pleural instillation of 7-N-(p-hydroxyphenyl)-mitomycin C (KW-2083), a derivative of mitomycin C." | 3.67 | [Effect of 7-N-(P-hydroxyphenyl)-mitomycin C (KW-2083) against pleuritis carcinomatosa]. ( Eguchi, K; Garcia-Herreros, P; Hoshi, A; Nomori, H; Saijo, N; Sasaki, Y; Shimizu, E; Shinkai, T; Tominaga, K, 1984) |
| "To evaluate the tolerance of peritonectomy procedures (PP) combined with intraperitoneal chemohyperthermia (IPCH) in patients with peritoneal carcinomatosis (PC), a phase II study was carried out from January 1998 to September 2001." | 2.71 | Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. ( Beaujard, AC; Francois, Y; Freyer, G; Gilly, FN; Glehen, O; Guertsch, P; Mithieux, F; Osinsky, D; Panteix, G; Peyrat, P; Vignal, J, 2003) |
| " Pharmacokinetic data from these patients showed very low plasma levels both for KW-2149, as for both known metabolites M-16 and M-18." | 2.68 | Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion. ( Ardiet, C; Catimel, G; De Bruijn, E; Dirix, L; Tranchand, B; Van Oosterom, A; Verdonk, R, 1995) |
| "Among advanced ovarian cancer, OCCA has worse prognosis compared with serous cystadenocarcinoma because of its poor sensitivity to CDDP-based chemotherapy (CTX)." | 2.68 | [Successful treatment of clear cell adenocarcinoma of the ovary (OCCA) with a combination of CPT-11 and mitomycin C]. ( Hasumi, K; Shimizu, Y; Umezawa, S, 1996) |
| "Among gynecologic cancers, ovarian cancer is treated with chemotherapy as a routine practice." | 2.41 | [Gynecologic cancer-evidenced based chemotherapy]. ( Ochiai, K, 2000) |
| "Occasional advanced cervical cancer patients do not meet the eligibility criteria because of renal dysfunction due to involvement of ureter." | 2.40 | [Consecutive low-dose cisplatin-based chemotherapy for gynecologic malignancies]. ( Shimizu, Y, 1997) |
| "Mitomycin-C (MMC) was used in 20% and oxaliplatin in 10%." | 1.56 | Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies. ( Ashwin, KR; Kumar C, R; Rauthan, A; Somashekhar, SP; Yethadka, R; Zaveri, S, 2020) |
| "Pseudomyxoma peritonei is rare, almost always of appendiceal origin, and presents in various ways relevant to abdominal surgeons." | 1.56 | Mode of Presentation in 1070 Patients With Perforated Epithelial Appendiceal Tumors, Predominantly with Pseudomyxoma Peritonei. ( Cecil, TD; Chandrakumaran, K; Dayal, S; Mohamed, F; Moran, BJ; Shariff, US, 2020) |
| "VEGF111b mRNA was detected in ovarian cancer cell lines SKOV3 and OVCAR3 by RT-PCR." | 1.42 | VEGF111b, a C-terminal splice variant of VEGF-A and induced by mitomycin C, inhibits ovarian cancer growth. ( Gu, F; He, D; Kong, J; Li, N; Li, X; Liu, Z; Niu, C; Pan, B; Wang, X; Wang, Y; Yao, Y; Zhang, S; Zheng, L, 2015) |
| "Ovarian cancer was transplanted i." | 1.42 | [Intraperitoneal chemotherapy--a method of improving treatment effectiveness in ovarian cancer]. ( Alexandrov, VA; Belyaev, AM; Belyaeva, OA; Bespalov, VG; Kireeva, GS; Kopteva, OS; Krasilnikova, LA; Maidin, MA; Semenov, AL; Stukov, AN; Vasilieva, IN; Vyshinskaya, EA, 2015) |
| "Mitomycin C (88." | 1.40 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. ( Hiotis, S; Jibara, G; Labow, DM; Romanoff, A; Sarpel, U; Shrager, B; Tabrizian, P; Yang, MJ, 2014) |
| "and compound 7c exhibit good anticancer activity against ovary (IGR-OV-1), breast (MCF-7) and CNS(SF-295) human cancer cell lines." | 1.36 | Solvent free synthesis, anti-inflammatory and anticancer activity evaluation of tricyclic and tetracyclic benzimidazole derivatives. ( Agrawal, SK; Rani, R; Roy, P; Saxena, AK; Singh, J; Sondhi, SM, 2010) |
| "Finally, the growth and metastasis of KGN cells injected subcutaneously (s." | 1.35 | Spontaneous transformation of human granulosa cell tumours into an aggressive phenotype: a metastasis model cell line. ( Imai, M; Muraki, M; Saito, H; Seiki, M; Takahashi, Y; Takamatsu, K, 2008) |
| "Hereditary cases of breast and ovarian cancer are often attributed to germ-line mutations of the BRCA1 tumor suppressor gene." | 1.35 | E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks. ( Baer, R; Cheng, JT; Jasin, M; Lokshin, M; Ludwig, T; Modi, AP; Reid, LJ; Shakya, R, 2008) |
| "Eligible patients with ovarian cancer in whom pre-operative evaluation indicated that there was a good possibility that disease could be resected to < or = 5 mm underwent surgery followed by intraperitoneal perfusion of cisplatin (100 mg/m2) or mitomycin C (30-40 mg total dose) heated to 41-43 degrees C (105." | 1.34 | Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. ( Edwards, RP; Gordinier, ME; Helm, CW; Martin, RS; Metzinger, DS; Parker, LP; Randall-Whitis, L, 2007) |
| "A 59-year-old woman with advanced ovarian cancer complained of massive refractory ascites after 2 years' history of chemotherapy." | 1.32 | [A patient with stage IIIc ovarian cancer with massive ascites who was chemotherapy resistant showed complete response with intraperitoneal hyperthermic chemoperfusion]. ( Fujimoto, S; Kobayashi, K; Mutou, T; Ogasawara, T; Ohtsuka, Y; Takahashi, M; Toyosawa, T, 2003) |
| "Expanded gammadeltaTILs from colorectal tumors demonstrated marked cytotoxicities to allogeneic human colon adenocarcinoma HR8348 and lymphoma Daudi cells, as well as xenogeneic murine thymoma EL-4 cell lines." | 1.31 | Antitumor activity of expanded human tumor-infiltrating gammadelta T lymphocytes. ( Ba, D; Chen, J; He, W; Niu, H, 2001) |
| " To explain this tumor selectivity, the distribution of FK317 was investigated after dosing tumor-bearing mice with the 14C-labelled compound." | 1.30 | FK317, a novel substituted dihydrobenzoxazine, exhibits potent antitumor activity against human tumor xenografts in nude mice. ( Fujiwara, T; Inami, M; Kawamura, I; Manda, T; Matsumoto, S; Naoe, Y; Nishigaki, F; Shimomura, K; Takagaki, S; Tsujimoto, S; Yamazaki, S, 1998) |
| " Dose-response curves (DRCs) were calculated by non-linear (sigmoid model: SigmaPlot) and linear curve fitting (median-effect analysis: CalcuSyn)." | 1.30 | Sigmoid model versus median-effect analysis for obtaining dose-response curves for in vitro chemosensitivity testing. ( Petru, E; Pöch, G; Vychodil-Kahr, S, 1999) |
| "Long-term results of epithelial ovarian cancer were not favorable even in mucinous and endometrioid cell types." | 1.29 | Long-term follow-up of patients with epithelial carcinoma of the ovary. ( Arii, Y; Hattori, S; Kawai, M; Kikkawa, F; Ohta, M; Tomoda, Y, 1994) |
| "Fourteen patients with relapsing ovarian cancer were treated with Mitomycin C (Mit C) and 5 Fluorouracil (5-FU)." | 1.28 | Phase II study of mitomycin C and 5 fluorouracil in platinum resistant ovarian cancer. ( Covens, A; Mazurka, J; O'Connell, G; Rusthoven, J, 1992) |
| "This regimen is active in advanced ovarian cancer that has not responded to prior treatment and warrants further study combination with other active drugs as a first-line regimen for ovarian cancer." | 1.28 | Phase II study of combination 4'-epidoxorubicin and mitomycin C in recurrent epithelial ovarian cancer. ( Buxton, J; Chetiyawardana, A; Crawford, M; Lawton, F; Mould, J; O'Brien, M; Patterson, M; Redman, C; Stuart, N; Sykes, V, 1989) |
| "Intracarotid CDDP infusion in combination with angiotensin II was performed in two patients with metastatic brain tumor, lung carcinoma (LC) and ovarian carcinoma (OC)." | 1.27 | [Intracarotid arterial infusion with CDDP in combination with angiotensin II]. ( Hino, N; Mitsuhata, N; Nishigaki, S; Suga, K; Tagusagawa, Y, 1984) |
| "Individual ovarian cancers showed different sensitivities to the drugs." | 1.27 | [A new in vitro chemosensitivity test. Individualized chemotherapy against ovarian cancer and its clinical effect]. ( Ishige, H; Iwasawa, H; Sekiya, S; Takamizawa, H; Tanaka, N; Tokita, H, 1985) |
| "A case of an amylase-producing ovarian cancer in 69-year-old woman has been investigated by light and electron microscopy, as well as by amylase isozyme analysis." | 1.27 | [Amylase-producing ovarian cancer treated with postoperative QF chemotherapy--a case report]. ( Chiba, T; Hiura, M; Kaneko, H; Kawamurra, S; Moriwaki, S; Tanaka, M; Yokoyama, T, 1988) |
| "The effect of mitomycin C on two human ovarian cancer cell lines was measured during several exposure times and concentrations using the Human Tumour Colony-forming Assay (HTCA)." | 1.27 | Variations in exposure to mitomycin C in an in vitro colony-forming assay. ( de Bruijn, EA; Kuppen, PJ; Leeflang, P; Slee, PH; van den Berg, L; van Oosterom, AT, 1986) |
| "A case of brain metastasis in ovarian cancer is reported." | 1.27 | [Metastatic brain tumor after chemotherapy of ovarian cancer]. ( Chen, JT; Fujimoto, I; Fukuda, K; Hasumi, K; Masubuchi, K; Sakamoto, A; Yamauchi, K, 1987) |
| " The clinical course of this case had decided for us which route would be the most effective and would have the least side effect, also, how much of a dosage can be administered as a maximum adoptive dose of an anti-cancer agent, and what kind of a second-line chemotherapy is effective against resistant cancer cells." | 1.27 | [A case report of an advanced ovarian cancer (stage T4) treated with a total amount of 1815 mg of CDDP]. ( Hino, K; Ibaraki, T; Katou, Y; Kiyozuka, Y; Maruyama, M; Nabuchi, K; Ninomiya, Y; Noda, T; Okamura, Y; Oku, M, 1987) |
| " Drug dose-response and time-response curves were plotted, and the IC50 ratio was calculated, for each test compound in order to investigate the mechanism of anticancer action." | 1.27 | [In vitro sensitivity test of a cultured human ovarian cancer cell line to anticancer agents]. ( Fujiya, S; Hatiya, S; Nakabayashi, Y; Tahira, K; Terashima, Y; Yasuda, M; Yoshioka, M, 1985) |
| "Out of 15 evaluable cases, a case of ovarian cancer showed a partial response." | 1.27 | [A clinical trial of a new mitomycin C derivative, KW-2083 (7-N-(p-hydroxyphenyl)-mitomycin C)]. ( Takahashi, H; Takahashi, K; Wakui, A; Yokoyama, M, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 42 (29.79) | 18.7374 |
| 1990's | 40 (28.37) | 18.2507 |
| 2000's | 29 (20.57) | 29.6817 |
| 2010's | 26 (18.44) | 24.3611 |
| 2020's | 4 (2.84) | 2.80 |
| Authors | Studies |
|---|---|
| Kunz, KR | 1 |
| Iyengar, BS | 1 |
| Dorr, RT | 2 |
| Alberts, DS | 4 |
| Remers, WA | 1 |
| Islam, I | 1 |
| Skibo, EB | 1 |
| Iwasa, K | 1 |
| Moriyasu, M | 1 |
| Yamori, T | 1 |
| Turuo, T | 1 |
| Lee, DU | 1 |
| Wiegrebe, W | 1 |
| Sondhi, SM | 1 |
| Rani, R | 1 |
| Singh, J | 1 |
| Roy, P | 1 |
| Agrawal, SK | 1 |
| Saxena, AK | 1 |
| Mendoza-Sánchez, F | 1 |
| Ángeles-Bueno, WG | 1 |
| Montes-López, GA | 1 |
| Mendoza-Medina, DF | 1 |
| Díaz-Sifuentes, JM | 1 |
| Pérez-Landeros, JE | 1 |
| Somashekhar, SP | 1 |
| Yethadka, R | 1 |
| Kumar C, R | 1 |
| Ashwin, KR | 1 |
| Zaveri, S | 1 |
| Rauthan, A | 1 |
| Codilupi, T | 1 |
| Taube, D | 1 |
| Naegeli, H | 1 |
| Costales, AB | 1 |
| Chambers, L | 1 |
| Chichura, A | 1 |
| Rose, PG | 1 |
| Mahdi, H | 1 |
| Michener, CM | 1 |
| Yao, M | 1 |
| Debernardo, R | 1 |
| Shariff, US | 1 |
| Chandrakumaran, K | 1 |
| Dayal, S | 1 |
| Mohamed, F | 1 |
| Cecil, TD | 1 |
| Moran, BJ | 1 |
| Arjona-Sanchez, A | 1 |
| Aziz, O | 1 |
| Passot, G | 2 |
| Salti, G | 2 |
| Esquivel, J | 1 |
| Van der Speeten, K | 1 |
| Piso, P | 1 |
| Nedelcut, DS | 1 |
| Sommariva, A | 1 |
| Yonemura, Y | 2 |
| Turaga, K | 1 |
| Selvasekar, CR | 1 |
| Rodriguez-Ortiz, L | 1 |
| Sanchez-Hidalgo, JM | 1 |
| Casado-Adam, A | 1 |
| Rufian-Peña, S | 1 |
| Briceño, J | 1 |
| Glehen, O | 3 |
| Gayarre, J | 1 |
| Martín-Gimeno, P | 1 |
| Osorio, A | 1 |
| Paumard, B | 1 |
| Barroso, A | 1 |
| Fernández, V | 1 |
| de la Hoya, M | 1 |
| Rojo, A | 1 |
| Caldés, T | 1 |
| Palacios, J | 1 |
| Urioste, M | 1 |
| Benítez, J | 1 |
| García, MJ | 1 |
| Morales-Soriano, R | 1 |
| Esteve-Pérez, N | 1 |
| Segura-Sampedro, JJ | 1 |
| Cascales-Campos, P | 1 |
| Barrios, P | 1 |
| Gorodnova, TV | 2 |
| Kotiv, KB | 1 |
| Ivantsov, AO | 1 |
| Mikheyeva, ON | 1 |
| Mikhailiuk, GI | 1 |
| Lisyanskaya, AS | 1 |
| Mikaya, NA | 1 |
| Guseynov, KD | 1 |
| Bondarev, NE | 1 |
| Matveyeva, NS | 1 |
| Nekrasova, EA | 1 |
| Sidoruk, AA | 1 |
| Roman, LD | 1 |
| Manikhas, GM | 1 |
| Belyaev, AM | 2 |
| Sokolenko, AP | 2 |
| Berlev, IV | 1 |
| Imyanitov, EN | 2 |
| Burgazli, KM | 1 |
| Mericliler, M | 1 |
| Kavukcu, E | 1 |
| Erdogan, A | 1 |
| Ertan, AK | 1 |
| Takata, K | 1 |
| Reh, S | 1 |
| Tomida, J | 1 |
| Person, MD | 1 |
| Wood, RD | 1 |
| Bakrin, N | 1 |
| Roux, AS | 1 |
| Vaudoyer, D | 1 |
| Gilly, FN | 4 |
| Cotte, E | 1 |
| Tabrizian, P | 1 |
| Shrager, B | 1 |
| Jibara, G | 1 |
| Yang, MJ | 1 |
| Romanoff, A | 1 |
| Hiotis, S | 1 |
| Sarpel, U | 1 |
| Labow, DM | 1 |
| Moiseyenko, VM | 1 |
| Chubenko, VA | 1 |
| Moiseyenko, FV | 1 |
| Zhabina, AS | 1 |
| Komarov, YI | 1 |
| Bogdanov, AA | 1 |
| Bhagwandin, S | 1 |
| Naffouje, S | 1 |
| Delhorme, JB | 1 |
| Triki, E | 1 |
| Romain, B | 1 |
| Meyer, N | 1 |
| Rohr, S | 1 |
| Brigand, C | 1 |
| Li, X | 1 |
| Gu, F | 1 |
| Niu, C | 1 |
| Wang, Y | 1 |
| Liu, Z | 1 |
| Li, N | 1 |
| Pan, B | 1 |
| He, D | 1 |
| Kong, J | 1 |
| Zhang, S | 1 |
| Wang, X | 1 |
| Yao, Y | 1 |
| Zheng, L | 1 |
| Bouhadjari, N | 1 |
| Gabato, W | 1 |
| Calabrese, D | 1 |
| Msika, S | 1 |
| Keita, H | 1 |
| Bespalov, VG | 2 |
| Vyshinskaya, EA | 2 |
| Vasilieva, IN | 1 |
| Maidin, MA | 2 |
| Semenov, AL | 2 |
| Stukov, AN | 2 |
| Kireeva, GS | 1 |
| Belyaeva, OA | 1 |
| Kopteva, OS | 1 |
| Krasilnikova, LA | 1 |
| Alexandrov, VA | 1 |
| Vasil'eva, IN | 1 |
| Barakova, NV | 1 |
| Imai, M | 1 |
| Muraki, M | 1 |
| Takamatsu, K | 1 |
| Saito, H | 1 |
| Seiki, M | 1 |
| Takahashi, Y | 1 |
| Yang, XJ | 1 |
| Li, Y | 1 |
| al-shammaa Hassan, AH | 1 |
| Yang, GL | 1 |
| Liu, SY | 1 |
| Lu, YL | 1 |
| Zhang, JW | 1 |
| Reid, LJ | 1 |
| Shakya, R | 1 |
| Modi, AP | 1 |
| Lokshin, M | 1 |
| Cheng, JT | 1 |
| Jasin, M | 1 |
| Baer, R | 1 |
| Ludwig, T | 1 |
| Kanagavel, D | 1 |
| Pokataev, IA | 1 |
| Fedyanin, MY | 1 |
| Tryakin, AA | 1 |
| Bazin, IS | 1 |
| Narimanov, MN | 1 |
| Yakovleva, ES | 1 |
| Garin, AM | 1 |
| Tjulandin, SA | 1 |
| Hayakawa, T | 1 |
| Zhang, F | 1 |
| Hayakawa, N | 1 |
| Ohtani, Y | 1 |
| Shinmyozu, K | 1 |
| Nakayama, J | 1 |
| Andreassen, PR | 1 |
| Parson, EN | 1 |
| Lentz, S | 1 |
| Russell, G | 1 |
| Shen, P | 1 |
| Levine, EA | 1 |
| Stewart, JH | 1 |
| Vogl, TJ | 1 |
| Naguib, NN | 1 |
| Lehnert, T | 1 |
| Nour-Eldin, NE | 1 |
| Eichler, K | 1 |
| Zangos, S | 1 |
| Gruber-Rouh, T | 1 |
| Kim, KK | 1 |
| Lange, TS | 1 |
| Singh, RK | 1 |
| Brard, L | 1 |
| Moore, RG | 1 |
| Deraco, M | 2 |
| Virzì, S | 1 |
| Iusco, DR | 1 |
| Puccio, F | 1 |
| Macrì, A | 1 |
| Famulari, C | 1 |
| Solazzo, M | 1 |
| Bonomi, S | 1 |
| Grassi, A | 1 |
| Baratti, D | 2 |
| Kusamura, S | 2 |
| Cui, S | 1 |
| Ba, M | 1 |
| Tang, Y | 1 |
| Liu, J | 1 |
| Wu, Y | 1 |
| Wang, B | 1 |
| Zhang, X | 1 |
| Tang, H | 1 |
| Zhong, S | 1 |
| Eveno, C | 1 |
| Goéré, D | 1 |
| Dartigues, P | 1 |
| Honoré, C | 1 |
| Dumont, F | 1 |
| Tzanis, D | 1 |
| Benhaim, L | 1 |
| Malka, D | 1 |
| Elias, D | 1 |
| Li, L | 1 |
| Chen, DB | 1 |
| Lin, C | 1 |
| Cao, K | 1 |
| Wan, Y | 1 |
| Zhao, XY | 1 |
| Nie, CL | 1 |
| Yuan, Z | 1 |
| Wei, YQ | 1 |
| Mithieux, F | 1 |
| Osinsky, D | 1 |
| Beaujard, AC | 1 |
| Freyer, G | 1 |
| Guertsch, P | 1 |
| Francois, Y | 1 |
| Peyrat, P | 1 |
| Panteix, G | 2 |
| Vignal, J | 1 |
| Tanaka, H | 2 |
| Umekawa, T | 1 |
| Nagao, K | 1 |
| Ishihara, A | 2 |
| Toyoda, N | 1 |
| Wang, C | 1 |
| Gu, M | 1 |
| Wang, S | 1 |
| Ma, D | 1 |
| ISHIBASHI, Y | 1 |
| MYHRE, K | 1 |
| FJAERLI, J | 1 |
| OGIER, E | 1 |
| MAIJNELLI, M | 1 |
| PERITI, P | 1 |
| Kobayashi, K | 1 |
| Fujimoto, S | 1 |
| Takahashi, M | 1 |
| Mutou, T | 1 |
| Toyosawa, T | 1 |
| Ohtsuka, Y | 1 |
| Ogasawara, T | 1 |
| Ivanov, S | 2 |
| Zervoudis, S | 1 |
| Huang, X | 1 |
| Cai, SM | 2 |
| Tang, J | 1 |
| Li, ZT | 2 |
| Zang, RY | 2 |
| Aoki, Y | 2 |
| Kurata, H | 1 |
| Watanabe, M | 2 |
| Fujita, K | 2 |
| Tanaka, K | 2 |
| Izzo, L | 1 |
| Pierannunzi, F | 1 |
| Vari, A | 1 |
| Riccardi, S | 1 |
| Tarquini, S | 1 |
| Fermariello, A | 1 |
| Di Giorgio, A | 1 |
| Casullo, A | 1 |
| Caputo, M | 1 |
| Costi, U | 1 |
| Al Radhi, H | 1 |
| Kharrub, Z | 1 |
| Gazzanelli, S | 1 |
| Nishino, K | 1 |
| Amikura, T | 1 |
| Obata, H | 1 |
| Sekine, M | 1 |
| Yahata, T | 1 |
| Raspagliesi, F | 1 |
| Campos Torres, JC | 1 |
| de Souza, GA | 1 |
| Ditto, A | 1 |
| Zanaboni, F | 1 |
| Younan, R | 1 |
| Mariani, L | 1 |
| Laterza, B | 1 |
| Kihira, T | 1 |
| Nomura, Y | 1 |
| Pejovic, T | 1 |
| Yates, JE | 1 |
| Liu, HY | 1 |
| Hays, LE | 1 |
| Akkari, Y | 1 |
| Torimaru, Y | 1 |
| Keeble, W | 1 |
| Rathbun, RK | 1 |
| Rodgers, WH | 1 |
| Bale, AE | 1 |
| Ameziane, N | 1 |
| Zwaan, CM | 1 |
| Errami, A | 1 |
| Thuillier, P | 1 |
| Cappuccini, F | 1 |
| Olson, SB | 1 |
| Cain, JM | 1 |
| Bagby, GC | 1 |
| Helm, CW | 1 |
| Randall-Whitis, L | 1 |
| Martin, RS | 1 |
| Metzinger, DS | 1 |
| Gordinier, ME | 1 |
| Parker, LP | 1 |
| Edwards, RP | 1 |
| Edwards, SL | 1 |
| Brough, R | 1 |
| Lord, CJ | 1 |
| Natrajan, R | 1 |
| Vatcheva, R | 1 |
| Levine, DA | 1 |
| Boyd, J | 1 |
| Reis-Filho, JS | 1 |
| Ashworth, A | 1 |
| Takada, M | 2 |
| Ratanatharathorn, V | 1 |
| Samson, MK | 1 |
| Baker, LH | 1 |
| Pollard, R | 1 |
| Cummings, G | 1 |
| Fraile, RJ | 1 |
| Noda, T | 2 |
| Kosakai, H | 1 |
| Tsujimura, K | 1 |
| Nakanishi, A | 1 |
| Shintani, M | 1 |
| Kamamoto, Y | 1 |
| Shimamoto, I | 1 |
| Ichijo, M | 1 |
| Xu, ZD | 1 |
| Yajima, A | 1 |
| Abe, Y | 1 |
| Soh, K | 1 |
| Ozawa, N | 1 |
| Takabayashi, T | 1 |
| Sato, S | 1 |
| Uehara, S | 1 |
| Suzuki, M | 2 |
| Hamazoe, R | 1 |
| Koga, S | 1 |
| Maeta, M | 1 |
| Shimizu, N | 1 |
| Sumi, K | 1 |
| Oda, M | 1 |
| Karino, T | 1 |
| Yamane, T | 1 |
| Kanayama, H | 1 |
| Osaki, Y | 1 |
| Takahashi, T | 2 |
| Hagiwara, A | 2 |
| Ito, T | 2 |
| Van Weelde, BJ | 1 |
| Pauwels, EK | 1 |
| Jones, B | 1 |
| Van Oosterom, AT | 3 |
| Mitsuhata, N | 1 |
| Hino, N | 1 |
| Tagusagawa, Y | 1 |
| Suga, K | 1 |
| Nishigaki, S | 1 |
| Shimizu, E | 1 |
| Saijo, N | 1 |
| Shinkai, T | 1 |
| Eguchi, K | 1 |
| Tominaga, K | 1 |
| Nomori, H | 1 |
| Sasaki, Y | 1 |
| Garcia-Herreros, P | 1 |
| Hoshi, A | 1 |
| Noviello, E | 2 |
| Aluigi, MG | 1 |
| Cimoli, G | 2 |
| Rovini, E | 1 |
| Mazzoni, A | 1 |
| Parodi, S | 2 |
| De Sessa, F | 1 |
| Russo, P | 2 |
| Zhao, LR | 1 |
| Zhao, WX | 1 |
| Shao, MH | 1 |
| Peláez, I | 1 |
| López, R | 1 |
| Palacio, I | 1 |
| Fernández, Y | 1 |
| Estrada, E | 1 |
| Esteban, E | 1 |
| Buesa, JM | 1 |
| Lacave, AJ | 1 |
| Kawai, M | 3 |
| Kikkawa, F | 1 |
| Hattori, S | 1 |
| Ohta, M | 3 |
| Arii, Y | 3 |
| Tomoda, Y | 4 |
| Dirix, LY | 1 |
| Gheuens, EE | 1 |
| van der Heyden, S | 1 |
| De Bruijn, EA | 3 |
| Hempling, RE | 1 |
| Piver, MS | 1 |
| Baker, TR | 1 |
| O'Neill Mullen, C | 1 |
| Reichman, B | 1 |
| Markman, M | 1 |
| Hakes, T | 1 |
| Rubin, S | 1 |
| Jones, W | 1 |
| Curtin, J | 1 |
| Barakat, R | 1 |
| Almadrones, L | 1 |
| Lewis, JL | 1 |
| Hoskins, W | 1 |
| Salle, B | 2 |
| Carry, PY | 2 |
| Sayag, A | 1 |
| Brachet, A | 2 |
| Braillon, G | 1 |
| Higashihara, J | 2 |
| Berens, ME | 1 |
| Collins, LA | 1 |
| Homesley, HD | 1 |
| Welander, CE | 1 |
| Dirix, L | 1 |
| Catimel, G | 1 |
| Verdonk, R | 1 |
| De Bruijn, E | 1 |
| Tranchand, B | 1 |
| Ardiet, C | 1 |
| Van Oosterom, A | 1 |
| Shimizu, Y | 5 |
| Umezawa, S | 3 |
| Hasumi, K | 4 |
| O'Dwyer, PJ | 1 |
| Perez, RP | 1 |
| Yao, KS | 1 |
| Godwin, AK | 1 |
| Hamilton, TC | 2 |
| Kaneyasu, Y | 1 |
| Okawa, MK | 1 |
| Kokubo, N | 1 |
| Takemoto, M | 1 |
| Karasawa, K | 1 |
| Fukuhara, N | 1 |
| Toda, J | 1 |
| Okawa, T | 1 |
| Morimoto, Y | 1 |
| Nakamura, M | 1 |
| Tamura, T | 1 |
| Kunii, T | 1 |
| Shimizu, K | 1 |
| Miyauchi, Y | 1 |
| Hoskins, PJ | 1 |
| Swenerton, KD | 1 |
| Pike, JA | 1 |
| McMurtrie, EM | 1 |
| Lee, N | 1 |
| Johnson, SW | 1 |
| Laub, PB | 1 |
| Beesley, JS | 1 |
| Ozols, RF | 1 |
| Agrawal, B | 1 |
| Krantz, MJ | 1 |
| Reddish, MA | 1 |
| Longenecker, BM | 1 |
| Viale, M | 1 |
| Pastrone, I | 1 |
| Pellecchia, C | 1 |
| Vannozzi, MO | 1 |
| Cafaggi, S | 1 |
| Esposito, M | 1 |
| Naoe, Y | 1 |
| Inami, M | 1 |
| Matsumoto, S | 1 |
| Takagaki, S | 1 |
| Fujiwara, T | 1 |
| Yamazaki, S | 1 |
| Kawamura, I | 1 |
| Nishigaki, F | 1 |
| Tsujimoto, S | 1 |
| Manda, T | 1 |
| Shimomura, K | 1 |
| Pöch, G | 1 |
| Vychodil-Kahr, S | 1 |
| Petru, E | 1 |
| Ochiai, K | 1 |
| Wu, Q | 1 |
| Kreienberg, R | 1 |
| Runnebaum, IB | 1 |
| Cavaliere, F | 1 |
| Perri, P | 1 |
| Di Filippo, F | 1 |
| Giannarelli, D | 1 |
| Botti, C | 1 |
| Cosimelli, M | 1 |
| Tedesco, M | 1 |
| Principi, F | 1 |
| Laurenzi, L | 1 |
| Cavaliere, R | 1 |
| Zhang, ZY | 1 |
| Chen, J | 2 |
| Tang, MQ | 1 |
| Liu, Q | 1 |
| Tanaka, T | 1 |
| Umesaki, N | 1 |
| Ogita, S | 1 |
| Shigematsu, T | 1 |
| Ohishi, Y | 1 |
| Fujita, T | 1 |
| Irie, T | 1 |
| Hayashi, T | 1 |
| Schuldes, H | 1 |
| Dolderer, JH | 1 |
| Zimmer, G | 1 |
| Knobloch, J | 1 |
| Bickeböller, R | 1 |
| Jonas, D | 1 |
| Woodcock, BG | 1 |
| Niu, H | 1 |
| He, W | 1 |
| Ba, D | 1 |
| Fushiki, H | 1 |
| Yuuki, H | 1 |
| Nakashima, A | 1 |
| Fujimura, M | 1 |
| Saito, S | 1 |
| Izumi, R | 1 |
| Furue, H | 1 |
| Ikeda, M | 1 |
| Tsukagoshi, S | 1 |
| Taguchi, T | 1 |
| Fujii, T | 1 |
| Rikimaru, T | 1 |
| Itamochi, H | 1 |
| Kigawa, J | 1 |
| Sultana, H | 1 |
| Iba, T | 1 |
| Akeshima, R | 1 |
| Kamazawa, S | 1 |
| Kanamori, Y | 1 |
| Terakawa, N | 1 |
| Orengo, G | 1 |
| Pagnan, G | 1 |
| Venturini, M | 1 |
| Conte, P | 1 |
| Schenone, F | 1 |
| Conzi, G | 1 |
| Sayag, AC | 1 |
| Bienvenu, J | 1 |
| Banssillon, V | 1 |
| Burgard, G | 1 |
| Manchon, M | 1 |
| Wada, Y | 2 |
| Tomiyoshi, Y | 1 |
| Fujimaru, J | 1 |
| Ogura, M | 1 |
| Hirabayashi, K | 1 |
| Yoshida, S | 2 |
| Takeda, Y | 3 |
| Benedetti Panici, P | 2 |
| Greggi, S | 2 |
| Scambia, G | 2 |
| Salerno, MG | 1 |
| Baiocchi, G | 1 |
| Cento, R | 2 |
| Mancuso, S | 2 |
| Inoue, M | 2 |
| Nakanishi, K | 2 |
| Ueda, G | 3 |
| Tanizawa, O | 3 |
| Covens, A | 1 |
| O'Connell, G | 1 |
| Rusthoven, J | 1 |
| Mazurka, J | 1 |
| Salerno, G | 1 |
| Werner, A | 2 |
| Mallmann, P | 1 |
| Chronides, A | 1 |
| Diedrich, K | 2 |
| Wagner, U | 1 |
| Krebs, D | 2 |
| Nakayama, T | 1 |
| Nakai, Y | 1 |
| Tamura, H | 1 |
| Nagano, T | 1 |
| Shibamoto, T | 1 |
| Ohara, A | 1 |
| Ozawa, M | 1 |
| Kurata, A | 1 |
| Mizuno, K | 1 |
| Furuhashi, Y | 1 |
| Maeda, O | 1 |
| Iwata, M | 1 |
| Misawa, T | 1 |
| Kano, T | 3 |
| Sawada, M | 2 |
| Yamasaki, M | 1 |
| Urabe, T | 1 |
| Ozaki, M | 2 |
| Yanagita, T | 2 |
| Takayama, K | 2 |
| Taki, I | 2 |
| Wu, YY | 1 |
| Usui, N | 1 |
| Yoshida, K | 1 |
| Hirayama, H | 1 |
| Takeuchi, H | 1 |
| Wada, H | 1 |
| Iwasa, T | 1 |
| Yamamoto, T | 1 |
| Nagasawa, I | 1 |
| Nakazawa, A | 1 |
| Ogawa, H | 1 |
| Shimizu, H | 1 |
| Saitoh, J | 1 |
| Tanaka, Y | 2 |
| Ihara, T | 1 |
| Hisamatsu, K | 1 |
| Okamoto, E | 1 |
| Suemitsu, H | 1 |
| Yamada, M | 1 |
| Matsuda, M | 1 |
| Nanba, K | 1 |
| Kirimoto, K | 1 |
| Sagawa, T | 2 |
| Yamashita, K | 2 |
| Kawamura, M | 2 |
| Shimizu, T | 2 |
| Haga, H | 1 |
| Yorozu, Y | 2 |
| Kasamo, M | 1 |
| Fujita, M | 1 |
| Takamizawa, H | 1 |
| Sekiya, S | 1 |
| Iwasawa, H | 1 |
| Ishige, H | 1 |
| Tokita, H | 1 |
| Tanaka, N | 1 |
| Miyake, H | 1 |
| Kohno, M | 1 |
| Nishiyama, S | 1 |
| Inoue, H | 1 |
| Ikeuchi, H | 1 |
| Sekigawa, S | 1 |
| Matsunaga, S | 1 |
| Ohkawa, K | 2 |
| Tsukada, Y | 2 |
| Umemoto, N | 2 |
| Hara, T | 2 |
| Hibi, N | 1 |
| Kawamurra, S | 1 |
| Hiura, M | 1 |
| Kaneko, H | 1 |
| Yokoyama, T | 1 |
| Tanaka, M | 1 |
| Chiba, T | 1 |
| Moriwaki, S | 1 |
| Inagaki, S | 1 |
| Yamashita, H | 1 |
| Imaizumi, H | 1 |
| Kakihara, M | 1 |
| Redman, C | 1 |
| Lawton, F | 1 |
| Stuart, N | 1 |
| O'Brien, M | 1 |
| Buxton, J | 1 |
| Mould, J | 1 |
| Chetiyawardana, A | 1 |
| Crawford, M | 1 |
| Patterson, M | 1 |
| Sykes, V | 1 |
| Yokota, T | 1 |
| Sawai, K | 1 |
| Yamaguchi, T | 1 |
| Shimotsuma, M | 1 |
| Sasabe, T | 1 |
| Ohyama, T | 1 |
| Takahashi, K | 2 |
| Kikuchi, J | 1 |
| Kishi, H | 1 |
| Saito, K | 1 |
| Mouri, H | 1 |
| Ikeno, N | 1 |
| Endo, H | 1 |
| Shima, I | 1 |
| Morizuka, T | 1 |
| Akiyoshi, T | 1 |
| Wada, T | 2 |
| Arinaga, S | 1 |
| Koba, F | 1 |
| Tsuji, H | 1 |
| Slee, PH | 1 |
| Leeflang, P | 1 |
| Kuppen, PJ | 1 |
| van den Berg, L | 1 |
| Fukuda, K | 1 |
| Chen, JT | 1 |
| Fujimoto, I | 1 |
| Yamauchi, K | 1 |
| Masubuchi, K | 1 |
| Sakamoto, A | 1 |
| Kimura, Y | 1 |
| Takizawa, K | 1 |
| Ino, Y | 1 |
| Isono, T | 1 |
| Sato, M | 1 |
| Iguchi, T | 1 |
| Yamashita, S | 1 |
| Kinashi, N | 1 |
| Yakabe, A | 1 |
| Tjaden, UR | 1 |
| van der Hoeven, RA | 1 |
| Jol, C | 1 |
| van der Greef, J | 1 |
| Lingeman, H | 1 |
| Maruyama, M | 1 |
| Kiyozuka, Y | 1 |
| Okamura, Y | 1 |
| Ibaraki, T | 1 |
| Katou, Y | 1 |
| Ninomiya, Y | 1 |
| Oku, M | 1 |
| Nabuchi, K | 1 |
| Hino, K | 1 |
| Inagaki, M | 1 |
| Hongo, J | 1 |
| Hirota, Y | 1 |
| Arimoto, Y | 1 |
| Adhvaryu, SG | 1 |
| Rawal, UM | 1 |
| Patel, JV | 1 |
| Garcia-Kendall, D | 1 |
| Surwit, EA | 1 |
| Bode, U | 1 |
| Musch, E | 1 |
| Fujiya, S | 1 |
| Yasuda, M | 1 |
| Tahira, K | 1 |
| Nakabayashi, Y | 1 |
| Yoshioka, M | 1 |
| Terashima, Y | 1 |
| Hatiya, S | 1 |
| Young, L | 1 |
| Mason, N | 1 |
| Salmon, SE | 1 |
| Senapad, S | 1 |
| Yokoyama, M | 1 |
| Takahashi, H | 1 |
| Wakui, A | 1 |
| Sakakibara, K | 1 |
| Casanova, H | 1 |
| Nishida, Y | 1 |
| Kazato, S | 1 |
| Miyazaki, T | 1 |
| Umemura, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cytoreductive Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy for the Treatment of Peritoneal Carcinomatosis From Gastrointestinal Cancer: an Open Label, Randomized, Prospective, Phase 2 Clinical Trial[NCT00454519] | Phase 2 | 60 participants (Anticipated) | Interventional | 2007-03-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for mitomycin and Ovarian Neoplasms
| Article | Year |
|---|---|
Use of synthetic stomata in abdominal carcinomatosis. Case report and literature review.
Topics: Adenocarcinoma, Papillary; Adult; Antineoplastic Combined Chemotherapy Protocols; Argon Plasma Coagu | 2019 |
Discovery of asymptomatic Krukenberg tumors diagnosed during caesarean section: therapy with hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2013 |
[Consecutive low-dose cisplatin-based chemotherapy for gynecologic malignancies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin; | 1997 |
Individualized chemotherapeutic regimen for each histological subtype of ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; C | 1997 |
[Gynecologic cancer-evidenced based chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Evidence-Based Medicine; Femal | 2000 |
20 trials available for mitomycin and Ovarian Neoplasms
| Article | Year |
|---|---|
Routine second-look after surgical treatment of colonic peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemo | 2015 |
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2009 |
A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring | 2010 |
B ultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Chemotherapy, Cancer, Regional Perfus | 2012 |
Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2003 |
Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; D | 2004 |
Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2005 |
Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in elderly Japanese patients with gynecological malignancies: a pilot study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Human | 2006 |
[Clinical trial of carmofur (HCFU) in the treatment of malignant ovarian cancer--The first report: combination therapy with endoxan, mitomycin C, and toyomycin].
Topics: Adult; Aged; Antineoplastic Agents; Chromomycin A3; Clinical Trials as Topic; Cyclophosphamide; Drug | 1983 |
Phase II study of mitomycin C plus 5-fluorouracil in patients with refractory ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Middle Aged; Mit | 1994 |
Lack of activity of 5-fluorouracil plus mitomycin-C as salvage therapy in cisplatin-resistant epithelial ovarian cancer: results of a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Cisp | 1994 |
Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion.
Topics: Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drugs, Inv | 1995 |
[Successful treatment of clear cell adenocarcinoma of the ovary (OCCA) with a combination of CPT-11 and mitomycin C].
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 1996 |
[Clinical evaluation of intra-arterial infusion chemotherapy for advanced or recurrent pelvic tumors with or without radiotherapy].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 1996 |
[Treatment of postoperative nausea and vomiting with ondansetron in patients administered anti-neoplastic agents].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; | 1996 |
A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Agents, Phytogenic; Antineoplas | 1998 |
[Clinical usefulness of ondansetron injection in patients receiving cancer chemotherapy].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cis | 2002 |
Treatment of malignant peritoneal effusion in digestive and ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplati | 1992 |
Mitomycin C and 5-fluorouracil salvage chemotherapy in platinum-resistant ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance; Female; Flu | 1992 |
Intermittent intensive combination chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (cyclic PAC chemotherapy) for ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Admin | 1992 |
116 other studies available for mitomycin and Ovarian Neoplasms
| Article | Year |
|---|---|
Structure-activity relationships for mitomycin C and mitomycin A analogues.
Topics: Animals; Breast Neoplasms; Chemical Phenomena; Chemistry; Colonic Neoplasms; Female; Humans; Leukemi | 1991 |
Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents.
Topics: Alkylation; Antineoplastic Agents; Aziridines; Benzimidazoles; Colonic Neoplasms; DNA; Female; Free | 1991 |
In vitro cytotoxicity of the protoberberine-type alkaloids.
Topics: Animals; Antineoplastic Agents, Phytogenic; Berberine; Berberine Alkaloids; Brain Neoplasms; Breast | 2001 |
Solvent free synthesis, anti-inflammatory and anticancer activity evaluation of tricyclic and tetracyclic benzimidazole derivatives.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; | 2010 |
Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neop | 2020 |
CRL4 ubiquitin ligase stimulates Fanconi anemia pathway-induced single-stranded DNA-RPA signaling.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Line, Tumor; Cell Su | 2019 |
Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Combined M | 2021 |
Mode of Presentation in 1070 Patients With Perforated Epithelial Appendiceal Tumors, Predominantly with Pseudomyxoma Peritonei.
Topics: Adenocarcinoma, Mucinous; Aged; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Appendicitis; Bi | 2020 |
Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Colonic Neoplasms; Cy | 2021 |
Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Breast Neoplasms; Carcinoma; Case-Control Studies; Cell | 2017 |
Current practice in cytoreductive surgery and HIPEC for metastatic peritoneal disease: Spanish multicentric survey.
Topics: Antineoplastic Agents; Carcinoma; Cardiac Output; Cisplatin; Colorectal Neoplasms; Cytoreduction Sur | 2018 |
Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cisplatin; Cytoreduction | 2018 |
Human DNA helicase HELQ participates in DNA interstrand crosslink tolerance with ATR and RAD51 paralogs.
Topics: Ataxia Telangiectasia Mutated Proteins; Base Sequence; Cell Line; Checkpoint Kinase 1; Cross-Linking | 2013 |
Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Cohort Stu | 2014 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Blood Transfusio | 2014 |
Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation.
Topics: Adult; Aged; Alkylating Agents; BRCA1 Protein; Female; Genetic Predisposition to Disease; Germ-Line | 2014 |
Utility of Chemoresponse Assay in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytoreductio | 2015 |
VEGF111b, a C-terminal splice variant of VEGF-A and induced by mitomycin C, inhibits ovarian cancer growth.
Topics: Alternative Splicing; Animals; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Su | 2015 |
Hyperthermic intraperitoneal chemotherapy with cisplatin: Amifostine prevents acute severe renal impairment.
Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy P | 2016 |
[Intraperitoneal chemotherapy--a method of improving treatment effectiveness in ovarian cancer].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophos | 2015 |
Comparative Study of Antitumor Efficiency of Intraperitoneal and Intravenous Cytostatics in Experimental Rats with Disseminated Ovarian Cancer.
Topics: Adenocarcinoma, Papillary; Animals; Antineoplastic Agents; Ascites; Cisplatin; Female; Injections, I | 2017 |
Spontaneous transformation of human granulosa cell tumours into an aggressive phenotype: a metastasis model cell line.
Topics: Animals; Biomarkers, Tumor; Cell Growth Processes; Cell Line, Tumor; Disease Progression; Female; Gr | 2008 |
E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks.
Topics: Animals; BRCA1 Protein; Breast Neoplasms; Cell Line; Chromosome Aberrations; Cross-Linking Reagents; | 2008 |
MRG15 binds directly to PALB2 and stimulates homology-directed repair of chromosomal breaks.
Topics: Breast Neoplasms; Chromatin; Chromosome Breakage; Comet Assay; Cross-Linking Reagents; DNA; DNA Repa | 2010 |
Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Cancer, Regi | 2011 |
Initial experience with repetitive transarterial chemoembolization (TACE) as a third line treatment of ovarian cancer metastasis to the liver: indications, outcomes and role in patient's management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Cisplatin; Deoxycyti | 2012 |
Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bl | 2012 |
Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovari | 2012 |
Ovarian metastasis is associated with retroperitoneal lymph node relapses in women treated for colorectal peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2013 |
hPNAS-4 inhibits proliferation through S phase arrest and apoptosis: underlying action mechanism in ovarian cancer cells.
Topics: Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; Carbon-Nitrogen Lyases; Caspase | 2013 |
Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in platinum- and paclitaxel-resistant epithelial ovarian cancer: case reports.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Carcinoma; Cispl | 2003 |
Comparative study on three chemotherapeutic regimens for the treatment of advanced epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplat | 2000 |
CANCER CHEMOTHERAPY (MITOMYCIN-C) FOLLOWED BY BONE MARROW TRANSPLANTATION.
Topics: Bone Marrow Transplantation; Breast Neoplasms; Carcinoid Tumor; Carcinoma, Bronchogenic; Choriocarci | 1964 |
TREATMENT OF MALIGNANT TUMOURS WITH 5-FLUOROURACIL IN 80 PATIENTS.
Topics: Biomedical Research; Breast Neoplasms; Colonic Neoplasms; Drug Therapy; Esophageal Neoplasms; Female | 1964 |
[CHEMOTHERAPY IN TREATMENT OF CARCINOMA OF THE OVARY].
Topics: Antineoplastic Agents; Aziridines; Cyclophosphamide; Drug Therapy; Female; Fluorouracil; Humans; Mit | 1964 |
[A patient with stage IIIc ovarian cancer with massive ascites who was chemotherapy resistant showed complete response with intraperitoneal hyperthermic chemoperfusion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplatin; Cystadenocarcinoma, Serous | 2003 |
[Metastatic cancer in transposed ovaries after radical Wertheim-Meigs hysterectomy for a stage I B and II A cervical cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Cisplatin; Etoposide; Fema | 2003 |
[Multidisciplinary treatment of recurrent epithelial ovarian carcinoma and prognostic analysis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Comb | 2004 |
[Anaesthesiologic problems about hyperthermic intraoperative intraperitoneal chemotherapy].
Topics: Adult; Anesthesia; Antibiotics, Antineoplastic; Antineoplastic Agents; Cisplatin; Female; Hemodynami | 2004 |
Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2006 |
Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer.
Topics: Adult; Aged; Chromosome Breakage; DNA Methylation; DNA, Complementary; Epithelial Cells; Fanconi Ane | 2006 |
Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Fem | 2007 |
Resistance to therapy caused by intragenic deletion in BRCA2.
Topics: Aged; Alleles; Amino Acid Sequence; Base Sequence; BRCA2 Protein; Carboplatin; Cell Line, Tumor; Chr | 2008 |
[Nonspecific cell-mediated immunity of gynecologic cancer patients and related effects of chemotherapy and immunotherapy].
Topics: Female; Fluorouracil; Humans; Immunity, Cellular; Leukocyte Count; Mitomycin; Mitomycins; Ovarian Ne | 1983 |
Combination chemotherapy with mitomycin C, adriamycin, and cyclophosphamide (MAC) in stage III and IV ovarian cancer.
Topics: Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Humans; Middle Aged; Mitomycin; Mi | 1983 |
Effects of radiotherapy and chemotherapy on sister chromatid exchanges in peripheral lymphocytes of the patients with gynecologic cancer.
Topics: Choriocarcinoma; Crossing Over, Genetic; Female; Genital Neoplasms, Female; Humans; Lymphocytes; Mit | 1983 |
[Serum levels of mitomycin C following a high-dose continuous hyperthermic peritoneal perfusion].
Topics: Female; Hot Temperature; Humans; Lung Neoplasms; Mitomycin; Mitomycins; Ovarian Neoplasms; Perfusion | 1984 |
[Intraabdominal administration of MMC adsorbed on activated carbon for management of carcinomatous peritonitis].
Topics: Abdomen; Carbon; Colonic Neoplasms; Female; Gastrointestinal Neoplasms; Humans; Middle Aged; Mitomyc | 1984 |
Scintigraphic peritoneography in advanced ovarian malignancies: its value for chemotherapeutic distribution studies.
Topics: Adult; Aged; Catheterization; Female; Humans; Infusions, Parenteral; Middle Aged; Mitomycin; Mitomyc | 1984 |
[Intracarotid arterial infusion with CDDP in combination with angiotensin II].
Topics: Adenocarcinoma, Papillary; Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Bra | 1984 |
[Effect of 7-N-(P-hydroxyphenyl)-mitomycin C (KW-2083) against pleuritis carcinomatosa].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Agents; Colonic Neoplasms; Female; Fever; Huma | 1984 |
Sister-chromatid exchanges, chromosomal aberrations and cytotoxicity produced by topoisomerase II-targeted drugs in sensitive (A2780) and resistant (A2780-DX3) human ovarian cancer cells: correlations with the formation of DNA double-strand breaks.
Topics: Antineoplastic Agents; Cell Survival; Chromosome Aberrations; DNA Damage; DNA, Neoplasm; Doxorubicin | 1994 |
[Treatment of advanced and recurrent gynecologic cancer with chemotherapy by cannula perfusion into both internal iliac arteries].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1994 |
Long-term follow-up of patients with epithelial carcinoma of the ovary.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; Cytarabine; | 1994 |
Cytotoxic activity of 7-N-(2-((2-(-gamma-L-glutamylamino)- ethyl)dithio)ethyl)-mitomycin C and metabolites in cell lines with different resistance patterns.
Topics: Animals; Colonic Neoplasms; Drug Resistance; Drug Screening Assays, Antitumor; Female; Humans; Kinet | 1994 |
Mitomycin-C plus a 3-day continuous intravenous infusion of 5-fluorouracil: an inactive salvage regimen for platinum-resistant ovarian carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance | 1993 |
[Intraperitoneal chemo-hyperthermia in the treatment of peritoneal carcinomatosis of ovarian origin. Initial cases, physiopathologic data].
Topics: Aged; Carcinoma; Cisplatin; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Inject | 1993 |
Combined antiproliferative activity of 5-fluorouracil and mitomycin-C against primary human ovarian tumors and cell lines in a clonogenic assay.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administratio | 1993 |
[The results of chemosensitivity test for clear cell adenocarcinoma of the ovary].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; | 1996 |
Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines.
Topics: Antineoplastic Agents; Cell Hypoxia; Cisplatin; Drug Resistance, Neoplasm; Female; Glutamate-Cystein | 1996 |
"MECCA": a developmental, dose-intensive, non-cross-resistant platinum-based chemotherapy for advanced ovarian cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Fr | 1996 |
Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.
Topics: Antineoplastic Agents; Cisplatin; DNA Damage; DNA Repair; Dose-Response Relationship, Drug; Doxorubi | 1997 |
Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2.
Topics: Antibodies, Monoclonal; Antigens, CD; Apoptosis; Ascitic Fluid; CD28 Antigens; Cells, Cultured; Chro | 1998 |
Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1998 |
FK317, a novel substituted dihydrobenzoxazine, exhibits potent antitumor activity against human tumor xenografts in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biotransformation; Body Weight; Carcinoma, Large Cel | 1998 |
Sigmoid model versus median-effect analysis for obtaining dose-response curves for in vitro chemosensitivity testing.
Topics: Antibiotics, Antineoplastic; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Humans; Lin | 1999 |
Growth suppression of human ovarian carcinoma OV-MZ-2a and OV-MZ-32 cells mediated by gene transfer of wild-type p53 enhanced by chemotherapy in vitro.
Topics: Adenocarcinoma; Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cis | 2000 |
Treatment of peritoneal carcinomatosis with intent to cure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colorectal Neoplasms; Combined | 2000 |
Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; | 2000 |
Camptothecin and mitomycin combination chemotherapy on ovarian clear cell carcinoma with multiple systemic metastases.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Admin | 2000 |
Metastatic carcinoma in a transposed ovary after radical hysterectomy for a stage 1B cervical adenosquamous cell carcinoma. Case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Cisplatin; Etoposid | 2000 |
Reversal of multidrug resistance and increase in plasma membrane fluidity in CHO cells with R-verapamil and bile salts.
Topics: Animals; Antineoplastic Agents; Cell Division; CHO Cells; Cisplatin; Cricetinae; Cricetulus; Doxorub | 2001 |
Antitumor activity of expanded human tumor-infiltrating gammadelta T lymphocytes.
Topics: Adenocarcinoma; Adult; Aged; Animals; Cytokines; Cytotoxicity Tests, Immunologic; Female; Humans; Im | 2001 |
[Apoptosis as a measure of chemosensitivity to anti-cancer drugs in gynecological cancer].
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cisplatin; Drug Screening Assays, Antitumor | 2002 |
Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
Topics: Adenocarcinoma, Clear Cell; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 2002 |
Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation.
Topics: Camptothecin; Cell Death; Cisplatin; DNA Damage; DNA, Neoplasm; Drug Synergism; Epirubicin; Etoposid | 1992 |
[Sensitivity test for anti-tumor agents-3. MTT assay and its clinical effect].
Topics: Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Screening Assays, Antitumor; F | 1992 |
Phase II study of mitomycin C and 5 fluorouracil in platinum resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Drug Resistance | 1992 |
Doxorubicin and cyclophosphamide, alternated with bleomycin and mitomycin C as a second-line regimen in advanced ovarian carcinoma resistant to cisplatin-based chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 1990 |
[Locoregional ascites therapy with cytostatic drugs and immune modulators in gynecologic neoplasms].
Topics: Ascites; Breast Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Interferon- | 1991 |
[A case of granulosa cell tumor with unusual histologic features].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Combined Modality Therapy; Cy | 1991 |
Mitomycin C cross-resistance induced by adriamycin in human ovarian cancer cells in vitro.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Cystadenocarcinoma; DNA, Neop | 1990 |
Comparative study of combination chemotherapy of ovarian cancer: cyclophosphamide, adriamycin and cisplatin versus 5-fluorouracil, cyclophosphamide and mitomycin C.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1990 |
[Human LAK cell induction and its biological characteristics].
Topics: Antibodies, Monoclonal; Antigens, CD; Cytotoxicity Tests, Immunologic; Esophageal Neoplasms; Female; | 1990 |
[Cumulative survival rate of chemotherapy with CDDP for malignant ovarian tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1990 |
[Intermittent administration of the combination chemotherapy with cis-platin, adriamycin and cyclophosphamide (cyclic-PAC chemotherapy) for the ovarian cancers].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 1990 |
[Transformation of ovarian yolk sac tumor to immature teratoma following chemotherapy].
Topics: Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; | 1985 |
[Chemotherapy of ovarian cancer based on in vitro (HTCA) and in vivo (nude mice) chemosensitivity testing].
Topics: Animals; Antineoplastic Agents; Bleomycin; Cisplatin; Colony-Forming Units Assay; Combined Modality | 1985 |
[A new in vitro chemosensitivity test. Individualized chemotherapy against ovarian cancer and its clinical effect].
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Child; Cisplatin; Colony-Forming Units Assay; Cycloph | 1985 |
[A case of amylase-producing ovarian tumor].
Topics: Amylases; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma; Cytarabine; Female; Fl | 1986 |
[Anti-tumor activity of an anti-human alpha-fetoprotein antibody-human serum albumin-mitomycin C conjugate against human yolk sac tumor maintained in vitro and in nude mice in vivo].
Topics: alpha-Fetoproteins; Animals; Antibodies; Antibody Specificity; Cytotoxicity, Immunologic; Female; Hu | 1986 |
Selective in vitro and in vivo growth inhibition against human yolk sac tumor cell lines by purified antibody against human alpha-fetoprotein conjugated with mitomycin C via human serum albumin.
Topics: Adolescent; alpha-Fetoproteins; Animals; Antibodies; Cell Line; Female; Humans; Mesonephroma; Mice; | 1986 |
[Amylase-producing ovarian cancer treated with postoperative QF chemotherapy--a case report].
Topics: Amylases; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma; Female; Humans; Middle | 1988 |
[Changes in CA125 concentration in ovarian cancer patients during the remission state--mean attenuating curve and the effectiveness of surgery and chemotherapy].
Topics: Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 1989 |
Phase II study of combination 4'-epidoxorubicin and mitomycin C in recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Epirubicin; Female; Hu | 1989 |
Mitomycin C adsorbed on activated carbon particles: is intraperitoneal chemotherapy effective for synchronous pleuritis carcinomatosa?
Topics: Adult; Female; Humans; Injections, Intraperitoneal; Krukenberg Tumor; Mitomycin; Mitomycins; Ovarian | 1989 |
[An analysis of factors influential in improving the survival rate of patients with ovarian cancer].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 1989 |
[Reductive effect on ascites, of neocarzinostatin in patients with ovarian cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Ascitic Fluid; Cisplatin; Female; Humans; Infusions, Intra | 1988 |
Enhanced chemosensitivity of cells from malignant effusions under condition of exposure to high temperature.
Topics: Ascitic Fluid; Breast Neoplasms; Cells, Cultured; Colonic Neoplasms; Colony-Forming Units Assay; Dox | 1986 |
Variations in exposure to mitomycin C in an in vitro colony-forming assay.
Topics: Cell Line; Cell Survival; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Female; Huma | 1986 |
[Metastatic brain tumor after chemotherapy of ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cisplatin; Cyclop | 1987 |
[Application of cytopathology in a sensitivity test for anti-tumor agents. I. An experimental study].
Topics: Animals; Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Colony-Forming Units Assay; Cytologica | 1987 |
[The effect of thermochemotherapy on ovarian cancer using human ovarian cancer xenograft transplanted to nude mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Fem | 1986 |
[Side effects and anti-cancer effects following intraperitoneal (ip) administration of mitomycin C (MMC)].
Topics: Female; Humans; Mitomycin; Mitomycins; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneum; Ut | 1987 |
[Clinical study of intraperitoneal chemotherapeutic perfusion (IPCP) of mitomycin C (MMC) and intraperitoneal administration of cisplatin].
Topics: Ascites; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Drug Therapy, Combination; Evaluation | 1987 |
Automated analysis of mitomycin C in body fluids by high-performance liquid chromatography with on-line sample pre-treatment.
Topics: Ascitic Fluid; Chromatography, High Pressure Liquid; Dialysis; Female; Humans; Microchemistry; Mitom | 1987 |
[A case report of an advanced ovarian cancer (stage T4) treated with a total amount of 1815 mg of CDDP].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cycloph | 1987 |
[Cisplatin, adriamycin and cyclophosphamide combination chemotherapy of epithelial ovarian cancer].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 1987 |
Enhancement of lymphocytic SCE frequencies in patients with ovarian cancer.
Topics: Adult; Aged; Carcinoma; Cell Division; Female; Humans; In Vitro Techniques; Lymphocytes; Middle Aged | 1988 |
Phase II trial of mitomycin C plus 5-FU in the treatment of drug-refractory ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Fluorouracil; | 1988 |
[Tolerance of intraoperative, intraperitoneal chemotherapy in advanced gynecologic malignancies].
Topics: Adolescent; Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Female | 1988 |
[In vitro sensitivity test of a cultured human ovarian cancer cell line to anticancer agents].
Topics: Animals; Antineoplastic Agents; Carbazilquinone; Cell Division; Cell Line; Cell Survival; Cells, Cul | 1985 |
In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration.
Topics: Anthraquinones; Antineoplastic Agents; Cisplatin; Colony-Forming Units Assay; Cytarabine; Doxorubici | 1985 |
Chemotherapy for gynecologic malignancies at Siriraj Hospital, Bangkok.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cyclophosphamid | 1985 |
[A clinical trial of a new mitomycin C derivative, KW-2083 (7-N-(p-hydroxyphenyl)-mitomycin C)].
Topics: Adult; Aged; Animals; Antibiotics, Antineoplastic; Biliary Tract Neoplasms; Colonic Neoplasms; Colon | 1985 |
[Effects of chemotherapy of advanced malignant ovarian tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Fluorouracil; Human | 1985 |